Gene and cell therapies for hearing loss are advancing fast, but cochlear implantation remains the proven, time-critical intervention for most children with deafness today.
Families of babies newly diagnosed with severe to profound hearing loss are already processing an enormous amount of new information: hearing aids, communication choices, imaging, genetics, surgery, rehabilitation and long-term follow-up. Increasingly, another question is arriving alongside all of this: ‘If my child’s deafness is genetic, should they have a cochlear implant, or should we wait for a potential future treatment?’ Some parents go further still: ‘Should we implant just one ear, and keep the other for a future therapy?’
These are not trivial questions. In April 2026 the FDA approved Otarmeni (Regeneron Pharmaceuticals), the first-ever gene therapy for genetic hearing loss, for patients with otoferlin (OTOF)-related deafness [1]. The first GJB2 gene therapy programmes have begun dosing patients, and the first cell therapy trial for hearing loss is expected to open next year. Regenerative medicine for hearing loss has moved from theoretical promise to early clinical reality within just a few years.
Yet cochlear implantation remains, for the great majority of children seen by implant teams today, the proven, available and time-sensitive intervention. This article sets out why, and where the genuine exceptions lie.
A fast-moving field, but still a narrow one
OTOF-related deafness (DFNB9) affects around one in 200,000 newborns. Dual adeno-associated virus (AAV)-mediated otoferlin gene delivery has now partially restored hearing in over 50 participants across multiple trials worldwide, culminating in Otarmeni’s approval [1]. GJB2, the most common known genetic cause of childhood hearing loss, is the next target: gene therapy programmes for GJB2 have begun dosing patients, with further candidates in development.
Notably, GJB2-related deafness arises from a problem confined to the cochlea itself – connexin 26 dysfunction – while the auditory nerve and central auditory pathways are unaffected. This is precisely why cochlear implant outcomes in GJB2-related deafness are already excellent – generally better than outcomes in children with most other genetic causes of deafness [2].
Figure 1: Timeline of key milestones in gene and cell therapy for hearing loss, 2026–2030+, set against the critical developmental window for spoken language in a child born today. Developed with assistance from Microsoft 365 Copilot, a GPT-5-based AI assistant.
However, more than 150 genes are linked to hereditary hearing loss, and genetic causes account for just under half of congenital deafness overall. Gene therapy is inherently mutation-specific: a therapy developed for OTOF will not treat GJB2, and vice versa. Some genes are too large for current gene therapy delivery systems, and the opportunity for effective treatment may diminish once auditory deprivation has occurred. In adults, who make up most of the deaf population, hearing loss typically results from a complex interplay of multiple genetic and non-genetic factors, making it poorly suited to a single-gene therapeutic approach. Gene therapy is likely to remain, for the foreseeable future, a solution for a minority of hearing loss causes, however important that minority is.
Cell therapy: broader potential, but further away
Cell therapy takes a different approach: replacing damaged cochlear cells rather than correcting one mutation, making it potentially applicable regardless of underlying cause. The wider stem cell field has matured rapidly. Over 100 clinical trials of human pluripotent stem cell (hPSC)-derived therapies are now underway globally, with more than 1200 patients treated and no consistent safety concerns [5]. Related regenerative cell therapies are already restoring reading ability in age-related macular degeneration, insulin independence in type 1 diabetes, and motor function in Parkinson’s disease – evidence that this class of therapy can deliver real clinical impact, not just preclinical promise.
The cochlea shares key features with these successful targets: small, well-defined, non-regenerating cell populations and a proven, safe surgical route for local delivery already provided by cochlear implant surgery itself. Rinri Therapeutic’s Rincell-1 programme, targeting neural hearing loss including presbycusis and post-synaptic auditory neuropathy, is on track to begin a first-in-human trial next year, delivered alongside cochlear implantation, not instead of it. Like most cell and gene therapies in this space, it remains investigational and some years from routine clinical availability.
Why waiting carries a real cost
There is strong, consistent evidence that earlier cochlear implantation produces better speech and language outcomes, particularly when implantation takes place within the first year of life. Five-year language outcomes are worse, on average, for every additional month of delay before intervention [3]. The developmental window for spoken language does not pause while a therapeutic pipeline matures.
"The most balanced message for families is one of optimism without delay: gene and cell therapy may shape the future, but early auditory access shapes the child’s present"
Should just one ear be implanted, preserving the other for a possible future therapy? The evidence argues against this too. Bilateral implantation supports sound localisation, listening in background noise and reduced listening effort, and the developing auditory brain is built to receive input from both ears. When one ear is deprived during this early, critical period, the auditory brain may never fully catch up: a phenomenon described as the aural preference syndrome [4]. There is also no evidence that bilateral implantation would prevent a child from receiving regenerative therapy in future, although it may influence which specific future therapies remain applicable.
Recommendations: implant now, test early
- Do not delay cochlear implantation while awaiting emerging therapies. For the great majority of children with severe to profound hearing loss, early and, where appropriate, bilateral cochlear implantation remains the standard of care. The evidence supporting early intervention is far stronger than the evidence for any currently investigational therapy.
- Identify the exceptions through early genetic testing. Among the most clinically relevant are OTOF-related deafness, for which an approved gene therapy now exists, and post-synaptic auditory neuropathy, where cochlear implantation alone has limited benefit. Early genetic testing is the only reliable way to identify these children and refer them appropriately, and is now endorsed by multiple organisations including the American College of Medical Genetics and Genomics, the American Academy of Pediatrics, the American Academy of Audiology, the British Society of Audiology, the European Academy of Otology and Neurotology and the NIH/NIDCD.
- Treat certain regenerative therapies as complementary to implantation, not a competing choice. Rincell-1 and similar programmes are being developed as adjuncts to cochlear implantation, not replacements for it. As the field matures, cell and gene therapies, alongside continued advances in implant technology, are likely to support increasingly personalised care in otology, rather than a binary ‘implant or wait’ decision.
Conclusion
Decisions have to be based on the treatments available today, not on hypothetical treatments that may become available in future. The most balanced message for families is one of optimism without delay: gene and cell therapy may shape the future, but early auditory access shapes the child’s present. We are writing this at a moment when the FDA has just approved a gene therapy for OTOF-related deafness, clinical trials of gene therapy for GJB2 – the most common cause of genetic childhood deafness – have only just begun, and cell therapy trials for hearing loss have yet to open.
We sincerely hope these approaches succeed. But for now, in a classic case of a bird in the hand, our advice to families remains that early, and where appropriate, bilateral cochlear implantation should not be delayed in the hope of a still-investigational alternative.
Click image to download a PDF of patient resource
Declaration of competing interests: DH is employed by Rinri Therapeutics and has shares in the company. HC has received reimbursement for conference attendance, speaker fees, fees for organising education, funds for research or fees for consulting from Advanced Bionics, Cochlear, MED-EL and Oticon Medical.
